

RESPONSE

A. Status of the Claims

Claims 16-42 were pending at the time of the Restriction Requirement, with claims 1-15 having been canceled in the Preliminary Amendment filed with the application on September 23, 2005. Claims 16-28 have been canceled herein, without prejudice or disclaimer, as being drawn to a non-elected invention in view of the election of the Group I invention made below in response to the Restriction Requirement. Claim 29 has been amended herein. Therefore, claims 29-42 are pending and presently under consideration in the case.

B. Response to Restriction Requirement


In response to the restriction requirement, Applicants elect, *without traverse*, to prosecute the Group II invention, as exemplified by claims 29-42, drawn to a method of using a pharmaceutical composition to enhance an antigen-specific type I immune response against an antigen. Applicants reserve the right to prosecute the Group I claims, or any other claims supported by the specification, in any continuing application.

C. Conclusion

Applicants believe this paper to be a full and complete response to the Restriction Requirement dated March 18, 2008. Applicants respectfully request favorable consideration of this case in view of the above comments and amendments.

Should the Examiner have any questions, comments, or suggestions relating to this case,
the Examiner is invited to contact the undersigned Applicants' representative at (512) 536-3035.

Respectfully submitted,

 Reg. No. 57,423
for Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
512.536.3035 (voice)
512.536.4598 (fax)
Date: May 15, 2008